DailyIQ
DailyIQ
Last updatedUpdating…

MEDP·Medpace Holdings, Inc.

$610.54
-24.58 (-3.88%)
After Hours
High
$636.99
Open
$632.75
Market Cap
17.08B
52W High
$693.97
Low
$605.49
P. Close
$610.54
P/E
32.98
52W Low
$373.00
Fwd P/E
30.74
DailyIQ Est.
$655.56
Inst. Own.
57.7%
Short Interest
4.91%
Days to Cover
3.5
NewEarnings release, scored · filed Oct 21, 2026New outlook issued · tone +1.3 vs prior release · 38 lines scoredSee the breakdown
Technical Score (1D)
50
NEUTRAL
News Sentiment
58
BULLISH
On Nov 20, Medpace Holdings reported third‑quarter 2026 earnings per share of $4.84, up 25.4 % year over year and exceeding consensus estimates by 8.76 %. Revenue for the quarter rose 8.5 % to $716 million, beating estimates by $1.02 million. Net new business awards reached $873.4 million, a 10.6 % increase from the prior quarter, and the trailing‑12‑month awards climbed 23.9 % to $3.02 billion. Backlog stood at $3.17 billion, higher than the previous quarter. These results suggest a solid operating performance and a growing order pipeline.
LOW TARGET
$370 -39.4%
2 analysts
MEAN TARGET
$651 +6.7%
14 analysts
HIGH TARGET
$730 +19.6%
6 analysts
PRICE RANGE
$370.00 - $730.00
SB / B / H / S / SS
2/5/13/1/1
DAILYIQ EST.
$655.56 (+7.4%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NMS
Country
United States
Symbol
MEDP
Description
Medpace Holdings, Inc. is a clinical research organization (CRO) specializing in drug and medical device development services across North America, Europe, and Asia. The company offers comprehensive support throughout the entire clinical trial lifecycle, from Phase I through Phase IV, catering to the pharmaceutical, biotechnology, and medical device sectors. Medpace's value lies in its integrated service offerings, including clinical trial design, project management, regulatory affairs guidance, and data analysis capabilities. Beyond these core services, the company provides specialized support such as central laboratory services, imaging, and electrocardiography support, positioning itself as a full-service partner for its clients. Founded in 1992, Medpace is headquartered in Cincinnati, Ohio.
Bought (1Y)
0 shares
$0
Sold (1Y)
374,529 shares
$230.2M
EWALD STEPHEN PGeneral Counsel & Corp. Secy.
Sell1,245 shares2026-10-29
BURWIG SUSAN EExec. VP, Operations
Sell3,940 shares2026-10-27
BURWIG SUSAN EExec. VP, Operations
Option Exercise328 shares2026-10-26
BURWIG SUSAN EExec. VP, Operations
Option Exercise328 shares2026-10-26
BURWIG SUSAN EExec. VP, Operations
Sell16,060 shares2026-10-26
78/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
17.8%
Revenue CAGR
21.6%
Current Ratio
0.74x
Return on Equity
98.3%
Earnings Summary
In the most recent quarter, Q3 2026, the company reported earnings per share of $4.84, up 25.4% year‑over‑year and surpassing consensus estimates by 8.76%, while revenue rose 8.5% to $716 million, beating estimates by $1.02 million; net new business awards increased 10.6% to $873.4 million and the trailing‑12‑month awards climbed 23.9% to $3.02 billion, with a backlog of $3.17 billion. Compared to Q2 2026, EPS grew from $4.25 to $4.84 and revenue from $707.3 million to $716 million, indicating a modest acceleration in earnings and a slight deceleration in revenue growth relative to the prior quarter. Over the past four quarters, Medpace has consistently beat analyst estimates in both EPS and revenue, with EPS growth ranging from 12% to 25% year‑over‑year and revenue growth hovering around 8–9% annually, demonstrating a stable upward trajectory in profitability and top‑line performance. Recent news highlights a strong operating performance and a growing order pipeline, with analysts raising earnings forecasts for the current quarter and noting elevated implied volatility that may signal a forthcoming event; these developments reinforce the bullish consensus and suggest that the company’s valuation metrics remain attractive relative to peers.

EPS

EstBeatMiss
$2.85$3.43$4.02$4.61$5.20Q4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$4.93 - -
Q3'26$4.46$4.84+8.5%
Q2'26$4.00$4.25+6.2%
Q4'25$4.23$4.67+10.5%
Q4'24$3.12$3.68+18.1%

Revenue

EstBeatMiss
$507M$571M$635M$698M$762MQ4'24Q4'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$733M - -
Q3'26$730M$716M-2.0%
Q2'26$701M$707M+0.8%
Q4'25$691M$708M+2.5%
Q4'24 - $537M -

Market Data

MEDP Stock Snapshot

NEUTRAL50/100
$605.49−$5.05 (0.8%)
Market cap
17.08B
P/E ratio
33.0
Day range
$605.49 – $636.99
News sentiment
58/100 · Neutral
Analyst target
$651.31 (+7.6%)
Consensus
Hold · 22 analysts
52-week range+62.3% off low · -12.7% from high
$373.00$693.97
Price $605.49 DailyIQ Est. $655.56

MEDP sits in the upper part of its 52-week range with the technical picture unresolved. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Behaviour On Record

What MEDP's own history says about today's numbers

Realized volatility (21d)
35.5% 50th pct
Below its peak
-11.9%
vs 200-day average
+14.5%
Up days (1y)
52%

Medpace Holdings, Inc. is currently running 35.5% annualised volatility over the last 21 sessions. Measured against MEDP's own 10 years of daily returns rather than a market-wide average, that is the 50th percentile — close to its own typical level, against a typical reading of 35.5%.

MEDP is trading -11.9% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -32.1%, and the deepest was -40.8% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +14.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 50th percentile — close to the gap it normally carries. Over the past year MEDP closed higher on 52% of sessions, and it is currently 3 sessions into a falling streak.

On November specifically: over 11 years of records, MEDP finished the month higher 6 of 11 times, with a median return of +2.2% and an average of +3.3%. Its strongest month historically has been July at +13.7% on average, its weakest February at -4.8%.

Overnight risk is measurable too: MEDP has opened more than 2% away from the prior close in 132 of 2,584 sessions (5.1% of the time), with the largest gaps running +24.0% and -15.8%.

Across the last 3 dated reports on file, MEDP moved an average of 5.5% in the session after earnings, closing higher 0 of those 3 times, with a median move of -2.9% and a largest of -11.6%.

All figures computed from 2,585 daily closes between 2016-08-11 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against MEDP's own 10-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of MEDP's sector?

Medpace Holdings, Inc. sits in the Industrials sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#8 of 12
Sector state
Leading
Sector rotation score
36

Options Market

What is the options market pricing for MEDP?

CallsPuts

For Medpace Holdings, Inc.'s nearest expiry (2026-12-18, 26 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 3.42), with at-the-money implied volatility around 47.9%. The options market is pricing roughly a ±12.5% move by that expiry — a range of about $529.91–$681.07.

Put/call ratio (2026-12-18)
3.42
ATM implied volatility
47.9%
Total open interest
2,691
Expected move by 2026-12-18
±12.5% ($529.91–$681.07)

Analyst Rating Changes

Are analysts turning bullish or bearish on MEDP?

BMO Capital most recently reiterated its rating on Medpace Holdings, Inc. to Market Perform on Oct 26, 2026 with a price target of $670 (from $600). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
BMO Capital: Market Perform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 26, 2026BMO CapitalMaintainedMarket Perform$600 → $670
Oct 23, 2026UBSMaintainedNeutral$673 → $700
Oct 23, 2026Truist SecuritiesMaintainedHold$609 → $633
Oct 23, 2026BarclaysMaintainedEqual-Weight$625 → $675
Oct 23, 2026TD CowenMaintainedHold$492 → $673
Oct 7, 2026MizuhoMaintainedOutperform$665 → $700
Oct 7, 2026BarclaysMaintainedEqual-Weight$600 → $625
Sep 30, 2026UBSUpgradeSell → Neutral$405 → $673
Jul 24, 2026MizuhoMaintainedOutperform$586 → $665
Jul 24, 2026BMO CapitalMaintainedMarket Perform$400 → $600
Jul 24, 2026Truist SecuritiesMaintainedHold$462 → $609
Jul 24, 2026TD CowenMaintainedHold$419 → $492

Earnings Release, Scored

What did Medpace Holdings, Inc.'s latest earnings release say?

Filed Oct 21, 2026 · SEC Form 8-K, Exhibit 99

New outlook issued
Tone76.9/ 100+1.3 vs prior release
Hedging words0.63per 100 words+0.32 vs prior release
Tone, last 3 releasesScale 50–82

Most important lines

  1. 1

    Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million as of September 30, 2025.

  2. 2

    On a constant currency basis, EBITDA for the third quarter of 2026 increased 16.0% from the third quarter of 2025.

  3. 3

    On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025.

Peers & ETF holders

MEDP peers & ETF holders

News & sentiment

What is the news saying about MEDP?

MEDP fell 1.9% over the month to Nov 20. News tone held between 21 and 75 from Oct 20 to Oct 28, then jumped to 89 on Oct 29.

Daily close and news tone, Oct 20 to Nov 20
$650$700Oct 20: tone 75Oct 21: tone 60Oct 22: tone 66Oct 23: tone 64Oct 26: tone 68Oct 27Oct 28: tone 21Oct 29: tone 89Oct 30: tone 52Nov 2: tone 73Nov 3Nov 4Nov 5: tone 81Nov 6: tone 39Nov 9Nov 10Nov 11: tone 70Nov 12Nov 13: tone 87Nov 16: tone 57Nov 17Nov 18: tone 75Nov 19Nov 20: tone 85Oct 20News toneNov 20123
  1. Oct 21 +4.9%same day: Medpace Holdings, Inc. Reports Third Quarter 2026 Results
  2. Oct 23 +4.4%same day: Medpace: 3 Key Takeaways for Long-Term Investors
  3. Oct 30 -3.8%same day: Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
Latest stories naming Medpace

Technical analysis

How strong is MEDP's momentum right now?

On the daily chart MEDP ranks at the 50th percentile for momentum against 1,063 stocks and ETFs, a neutral reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling MEDP?

85 of the 172 tracked managers added to MEDP in their latest 13F and 78 trimmed. Together they own 57.7% of the company, worth $10.1B. BlackRock and AQR Capital Management alone hold 14.0%.

85adding78trimming9unchanged
Largest holders by stake, latest 13FBar = share of MEDP
  1. $1.6B positionAdded 2.6% last quarter
  2. $863.2M positionAdded 9.2% last quarter
  3. $677.4M positionTrimmed 4.2% last quarter
  4. $627.9M positionTrimmed 2.0% last quarter
  5. $445.9M positionAdded 0.5% last quarter
  6. $444.7M positionAdded 0.3% last quarter
  7. $313.1M positionTrimmed 13.4% last quarter
  8. $312.0M positionAdded 16.5% last quarter
  9. $282.4M positionAdded 8.9% last quarter
  10. $282.0M positionTrimmed 4.5% last quarter
Full holdings history

Congressional trading

Is Congress trading MEDP?

4 members of Congress disclosed 10 MEDP trades between Jan 13, 2025 and May 15, 2026: 4 buys and 6 sells, about $104.5K in estimated value.

BuysSellsJan ’25AprJulOctJan ’26Apr
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has MEDP done against its peers?

Over the six months to Nov 20, MEDP returned +44.7%. Of the 15 related stocks and ETFs, 5 did better, led by CRL at +101.4%.

Change since May 20, through Nov 20
−50%0%+50%+100%+150%May 20JulAugSepOctNovNov 20CRL +101.4%MEDP +44.7%XLV +20.5%